Nektar Therapeutics (NKTR) to Release Quarterly Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) will be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect Nektar Therapeutics to post earnings of ($0.23) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). The business had revenue of $23.49 million for the quarter, compared to analysts’ expectations of $17.24 million. Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm posted ($0.27) EPS. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Trading Up 5.3 %

NASDAQ:NKTR opened at $1.40 on Wednesday. Nektar Therapeutics has a 1-year low of $0.41 and a 1-year high of $1.93. The firm has a market capitalization of $257.71 million, a price-to-earnings ratio of -1.56 and a beta of 0.61. The business’s fifty day moving average price is $1.28 and its 200 day moving average price is $1.34.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on NKTR shares. BTIG Research reaffirmed a “buy” rating and set a $4.00 price objective on shares of Nektar Therapeutics in a research report on Monday, September 30th. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research note on Monday. They issued an “overweight” rating and a $7.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $3.50.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.